These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 18452372

  • 1. Management of dry eye disease.
    Lemp MA.
    Am J Manag Care; 2008 Apr; 14(3 Suppl):S88-101. PubMed ID: 18452372
    [Abstract] [Full Text] [Related]

  • 2. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
    Wilson SE, Perry HD.
    Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
    [Abstract] [Full Text] [Related]

  • 3. [Effect of anti-inflammatory therapy on the treatment of dry eye syndrome].
    Mrukwa-Kominek E, Rogowska-Godela A, Gierek-Ciaciura S.
    Klin Oczna; 2007 Jan; 109(1-3):79-84. PubMed ID: 17687921
    [Abstract] [Full Text] [Related]

  • 4. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD, Pflugfelder SC, Tauber J, Foulks GN.
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [Abstract] [Full Text] [Related]

  • 5. Antiinflammatory therapy for dry eye.
    Pflugfelder SC.
    Am J Ophthalmol; 2004 Feb; 137(2):337-42. PubMed ID: 14962426
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
    Rao SN.
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
    [Abstract] [Full Text] [Related]

  • 13. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.
    Sacchetti M, Mantelli F, Lambiase A, Mastropasqua A, Merlo D, Bonini S.
    Br J Ophthalmol; 2014 Aug; 98(8):1016-22. PubMed ID: 24344232
    [Abstract] [Full Text] [Related]

  • 14. Advancements in anti-inflammatory therapy for dry eye syndrome.
    McCabe E, Narayanan S.
    Optometry; 2009 Oct; 80(10):555-66. PubMed ID: 19801339
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM, McGwin G, Liu B, Owsley C, Rosenstiel C.
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [Abstract] [Full Text] [Related]

  • 16. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME.
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [Abstract] [Full Text] [Related]

  • 17. Changing trends in the treatment of dry-eye disease.
    Dogru M, Nakamura M, Shimazaki J, Tsubota K.
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1581-601. PubMed ID: 24088227
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
    Leonardi A, Flamion B, Baudouin C.
    Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
    [Abstract] [Full Text] [Related]

  • 20. [Dry eye syndrom--multispecialistic disease. Part two: diagnostic procedure and treatment].
    Nowak M, Marek B, Kajdaniuk D, Siemińska L, Kos-Kudła B, Nowak K, Głogowska-Szelag J.
    Wiad Lek; 2011 Aug; 64(1):49-55. PubMed ID: 21812364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.